A Phase 1 Study of GS-0189 (formerly FSI-189) as Monotherapy and in Combination with Rituximab inPatients with Relapsed/RefractoryNon-Hodgkin Lymphoma.

Project: Research project

Project Details

Description

A Phase 1 Study of GS-0189 (formerly FSI-189) as Monotherapy and in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma.
StatusActive
Effective start/end date11/16/2111/16/26

Funding

  • Gilead Sciences, Inc.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.